Transplantation for colorectal liver metastases: lessons from TransMet and future challenges
- PMID: 40342761
- PMCID: PMC12057491
- DOI: 10.21037/hbsn-2025-51
Transplantation for colorectal liver metastases: lessons from TransMet and future challenges
Keywords: Liver transplantation (LT); TransMet trial; chemotherapy (CT); colorectal liver metastases (CRLM); unresectable metastases.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-51/coif). The authors have no conflicts of interest to declare.
Comment on
-
Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.Lancet. 2024 Sep 21;404(10458):1107-1118. doi: 10.1016/S0140-6736(24)01595-2. Lancet. 2024. PMID: 39306468 Clinical Trial.
References
-
- Adam R, Piedvache C, Chiche L, et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. Lancet 2024;404:1107-18. 10.1016/S0140-6736(24)01595-2 - DOI - PubMed
-
- Bond MJG, Bolhuis K, Loosveld OJL, et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol 2023;24:757-71. 10.1016/S1470-2045(23)00219-X - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources